Tag Archives: Erythropoietic Stimulating Agents

Affymax’s peginesatide one step closer to FDA approval

The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 15 to one, with one abstention, that peginesatide (formerly known as Hematide), demonstrated a favorable benefit/risk profile for use in the treatment of dialysis patients with anemia due … Continue reading

Posted in M Loghman-Adham, MD | Tagged , , | Leave a comment